SmithKline/Corixa Deal Gives SB Rights To HER-2 Breast Cancer Vaccine
Executive Summary
SmithKline Beecham will gain rights to Corixa's HER-2/neu breast cancer therapeutic vaccine under a licensing agreement between the two companies.
You may also be interested in...
GSK Gains Vaccine Adjuvant Technology With $300 Mil. Corixa Acquisition
GlaxoSmithKline will expand Corixa's vaccine adjuvant manufacturing capacity following the $300 mil. acquisition of the biotech company
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011